Company news
Imugene Ltd news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Appendix 4E & Annual Report to shareholders
August 31, 2020
Imugene Receives Third PD1-VAXX Ethics Trial Approval
August 20, 2020
Imugene Receives Clinical Guidance from US FDA for Vaxinia
August 5, 2020
Imugene Receives Second PD1-VAXX Ethics Trial Approval
July 16, 2020
Imugene Receives Ethics Approval to Start PD1-VAXX Trial
July 13, 2020
Imugene HER-Vaxx Phase 2 Clinical Update
May 3, 2020
Imugene PD1-Vaxx Immunotherapy Update
January 27, 2020
Imugene HER-Vaxx Immunotherapy Patent Granted in US
January 13, 2020
Imugene Share Placement to raise $24.6 million
December 1, 2019
Imugene Receives $4.13 million R&D Tax Incentive
November 4, 2019
US Defense Grant to Study Imugene CF33 Oncolytic Virotherapy
October 22, 2019
CF33 Oncolytic Virus Clinical Trial Program Update
October 20, 2019
Comprehensive Phase Ib HER-Vaxx Results Presented at ESMO
September 30, 2019
Investor Presentation - Proposed Acquisition
July 14, 2019
New HER-Vaxx Cancer Vaccine trial data presented at ESMO GI
July 7, 2019
Appendix 4C - Quarterly and Business Update
April 15, 2019
IMU presents new mimotope PD-1 vaccine data at AACR
April 2, 2019
IMU presents new KEY-Vaxx and B-Vaxx data at AACR
April 1, 2019
IMU Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx
March 19, 2019
Imugene doses first patient in HER-Vaxx phase 2 trial
March 13, 2019
IMU Announces Presentations on KEY-Vaxx and B-Vaxx at AACR
March 3, 2019
Pause in Trading
February 27, 2019
IMU Meets Endpoints in Phase 1b Gastric Cancer Trial
December 16, 2018
Imugene Advances to Phase 2 in Gastric Cancer Trial
November 12, 2018
Imugene Receives $1.85 million R&D Tax Incentive
November 8, 2018
Imugene commences cGMP manufacture of PD-1 cancer vaccine
September 20, 2018
Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment
September 10, 2018
Appendix 4E and Audited Financial Report
August 31, 2018
PD-1 cancer vaccine development update
July 22, 2018
Imugene raises $20.1 million
June 7, 2018
Imugene Licences Extensive B-Cell Immuno-Oncology Portfolio
June 6, 2018
Leslie Chong Appointed as Managing Director
March 27, 2018
Arginine Modulator Active in Cancer Models
February 18, 2018
Novel Anti-PD-1 Mimotope Vaccine Ready for Development
February 11, 2018
IMU Meets Investigator for Gastric Cancer Clinical Trial
February 8, 2018
Cancer vaccine shows early promise in clinical trial
February 6, 2018
Business Update - December Quarter Appendix 4C
January 28, 2018
Rights Issue Results & Shortfall Notification
December 19, 2017
Imugene raises $8.7 million
November 22, 2017
Response to ASX Price Query
October 16, 2017
IMU Receives $1.1m R&D Tax Refund
October 10, 2017
First Patient Dosing Commences of HER-Vaxx
August 30, 2017
Imugene granted Canadian patent for Her-Vaxx cancer vaccine
July 21, 2017
Appendix 4C - quarterly and Commentry Q3
April 28, 2017
IMU Raises $3.0m from Options Plan
April 6, 2017
$1.35 million Options Underwritten
March 29, 2017
Half Year Report and Accounts
February 28, 2017
Intellectual Property Strengthened Around Lead Clinical Drug
February 26, 2017
BMC Cancer journal publishes encouraging HER-Vaxx research
February 12, 2017
Imugene progresses mimotope platform
December 18, 2016
Decks
The 5 newest of 54 decks. Every deck is listed under its year.
- Investor Presentation (July 2026)
Investor deck · 29 slides · Jul 7, 2026
- Investor Presentation (March 2026)
Investor deck · 31 slides · Mar 11, 2026
- Technical Presentation (February 2026)
Technical · 15 slides · February 2026
- Shareholder Meeting (November 2025)
Shareholder meeting · 16 slides · Nov 13, 2025
- Shareholder Meeting (August 2025)
Shareholder meeting · 6 slides · Aug 20, 2025